Fuse Vectors, a Copenhagen, Denmark-based gene therapy company, raised $5.2M in Pre-Seed Funding.
The round was led by HCVC.
The company intends to use the funds to accelerate the development of its technology platform and pipeline of novel gene therapies.
Co-founded by Benjamin Blaha and Jordan Turnbull, and Henrik Stage, Executive Chair, Fuse Vectors is a biotech startup improving gene therapy with its cell-free viral vector technology, which combines component module libraries with on-demand biocatalytic AAV capsid filling processes. This eliminates cell-based production and offers improvements, reducing production time and costs while enhancing vector quality to meet patients unmet needs. Its technology offers:
- Clinically Viral Vector Titers: Increasing titers by orders of magnitude
- High capsid filling: >99% filled capsids
- Rapid Production: Viral vectors synthesized in hours.
- Optimization Feasibility: Rapid multi-parallel prototyping facilitates optimizing drug development across serotypes and constructs.
- Scalable process: Smooth transition from research to commercial stages.
Currently in alpha testing, Fuse Vectors is collaborating with over half a dozen partners – from academic research groups to leading pharmaceutical companies. The company plans two commercialization strategies: partnering with pharmaceutical companies, biotech firms, and academic institutions to optimize drug candidates using their Fuse Technology and Optimization Engine, while also developing their own pipeline of therapeutic candidates.
FinSMEs
25/02/2025